A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects With Diabetes, Dyslipidemia and Hypertension
Phase of Trial: Phase III
Latest Information Update: 21 Dec 2018
At a glance
- Drugs TRC 150094 (Primary)
- Indications Dyslipidaemias
- Focus Registrational; Therapeutic Use
- Sponsors Torrent Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 30 Jan 2018 Status changed from not yet recruiting to recruiting.
- 05 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Apr 2018.